1410 - Cancer and lung transplantation

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Cancer in Special Situations
Thoracic Malignancies
Presenter David Pérez Callejo
Authors D. Pérez Callejo1, R. Laporta2, E. Almagro Casado3, M. Palka3, A. Ruiz-Valdepeñas3, B. Cantos3, C. Maximiano3, M. Méndez García3, P. Ussetti2, M. Provencio Pulla4
  • 1Hospital Universitario Puerta de Hierro Majadahonda, 28222 - Madrid/ES
  • 2Pulmonology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid/ES
  • 3Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 - Madrid/ES
  • 4Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES



Malignacies rank fourth on the leading causes of death in recipients of solid organ transplantation. High-dose immunosuppression, infections with oncogenic viruses and the pre-transplant risk, mainly due to tobacco, make these patients more susceptible for developing cancer. In the present study we reviewed a collective of 50 patients with lung transplantation (LT) and cancer.

Patients and methods

Retrospective study of 503 lung transplant patients, performed at the Hospital Universitario Puerta de Hierro during 1993 and 2012. We included the following variables: date of birth, reason and date of transplantation, date of diagnosis of malignancy, histology and response to treatment, date and cause of exitus. The contrasts between proportions were performed using Chi-square test and survival curves using the product-limit method of Kaplan-Meier.


The 503 included transplant patients developed a total of 55 post-transplant malignancies in 50 patients. Four patients presented tumors already previous to the transplantation. The main underlying pathologies of the patient collective are idiopathic pulmonary fibrosis (50%), emphysema (30%) and cystic fibrosis (14%) The histology of the 55 post-transplant tumors were 18 skin cancer, 12 lung cancer, 8 gastrointestinal cancer, 6 Non-Hodgkin's Lymphoma, 2 bladder cancer, 2 myelodysplastic syndrome, 2 sarcomas and 5 others. The mean age of diagnosis of malignancies is at 59 years (18-68). The mean time from transplantation to tumor diagnosis amounts 4 years (1-15). Of the 21 patients (42%) that have died until data collection, cancer was death cause in 15 (30%)


Relying on our data, the majority of malignancies are skin and lung cancer and lymphoproliferative syndromes, attributing complications that should be considered in lung transplantation.


All authors have declared no conflicts of interest.